S&P 500   4,282.80 (+1.46%)
DOW   33,726.26 (+2.01%)
QQQ   355.24 (+0.92%)
AAPL   180.57 (+0.27%)
MSFT   334.61 (+0.61%)
META   274.23 (+0.59%)
GOOGL   125.08 (+1.10%)
AMZN   125.07 (+1.87%)
TSLA   216.79 (+4.47%)
NVDA   395.29 (-0.61%)
NIO   7.73 (+2.52%)
BABA   85.23 (+2.69%)
AMD   119.30 (-0.14%)
T   15.15 (-4.17%)
F   12.45 (+2.81%)
MU   68.77 (-0.46%)
CGC   0.84 (+1.10%)
GE   106.44 (+1.69%)
DIS   91.26 (+3.01%)
AMC   4.56 (+0.22%)
PFE   38.49 (+1.24%)
PYPL   64.31 (+2.00%)
NFLX   404.50 (+0.34%)
S&P 500   4,282.80 (+1.46%)
DOW   33,726.26 (+2.01%)
QQQ   355.24 (+0.92%)
AAPL   180.57 (+0.27%)
MSFT   334.61 (+0.61%)
META   274.23 (+0.59%)
GOOGL   125.08 (+1.10%)
AMZN   125.07 (+1.87%)
TSLA   216.79 (+4.47%)
NVDA   395.29 (-0.61%)
NIO   7.73 (+2.52%)
BABA   85.23 (+2.69%)
AMD   119.30 (-0.14%)
T   15.15 (-4.17%)
F   12.45 (+2.81%)
MU   68.77 (-0.46%)
CGC   0.84 (+1.10%)
GE   106.44 (+1.69%)
DIS   91.26 (+3.01%)
AMC   4.56 (+0.22%)
PFE   38.49 (+1.24%)
PYPL   64.31 (+2.00%)
NFLX   404.50 (+0.34%)
S&P 500   4,282.80 (+1.46%)
DOW   33,726.26 (+2.01%)
QQQ   355.24 (+0.92%)
AAPL   180.57 (+0.27%)
MSFT   334.61 (+0.61%)
META   274.23 (+0.59%)
GOOGL   125.08 (+1.10%)
AMZN   125.07 (+1.87%)
TSLA   216.79 (+4.47%)
NVDA   395.29 (-0.61%)
NIO   7.73 (+2.52%)
BABA   85.23 (+2.69%)
AMD   119.30 (-0.14%)
T   15.15 (-4.17%)
F   12.45 (+2.81%)
MU   68.77 (-0.46%)
CGC   0.84 (+1.10%)
GE   106.44 (+1.69%)
DIS   91.26 (+3.01%)
AMC   4.56 (+0.22%)
PFE   38.49 (+1.24%)
PYPL   64.31 (+2.00%)
NFLX   404.50 (+0.34%)
S&P 500   4,282.80 (+1.46%)
DOW   33,726.26 (+2.01%)
QQQ   355.24 (+0.92%)
AAPL   180.57 (+0.27%)
MSFT   334.61 (+0.61%)
META   274.23 (+0.59%)
GOOGL   125.08 (+1.10%)
AMZN   125.07 (+1.87%)
TSLA   216.79 (+4.47%)
NVDA   395.29 (-0.61%)
NIO   7.73 (+2.52%)
BABA   85.23 (+2.69%)
AMD   119.30 (-0.14%)
T   15.15 (-4.17%)
F   12.45 (+2.81%)
MU   68.77 (-0.46%)
CGC   0.84 (+1.10%)
GE   106.44 (+1.69%)
DIS   91.26 (+3.01%)
AMC   4.56 (+0.22%)
PFE   38.49 (+1.24%)
PYPL   64.31 (+2.00%)
NFLX   404.50 (+0.34%)
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Forecast, Price & News

$20.79
+0.49 (+2.41%)
(As of 01:33 PM ET)
Compare
Today's Range
$20.16
$20.89
50-Day Range
$16.97
$22.03
52-Week Range
$15.70
$36.13
Volume
280,445 shs
Average Volume
1.03 million shs
Market Capitalization
$1.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.44

Arcus Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
99.0% Upside
$41.44 Price Target
Short Interest
Bearish
18.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Arcus Biosciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$146,734 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.43) to ($3.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

516th out of 983 stocks

Pharmaceutical Preparations Industry

253rd out of 486 stocks


RCUS stock logo

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Arcus Biosciences (NYSE:RCUS) Trading 6.5% Higher
BTIG Sticks to Its Buy Rating for Arcus Biosciences (RCUS)
See More Headlines

RCUS Price History

RCUS Company Calendar

Last Earnings
5/09/2023
Today
6/02/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
366
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.44
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+101.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-267,000,000.00
Net Margins
-233.41%
Pretax Margin
-232.11%

Debt

Sales & Book Value

Annual Sales
$112 million
Book Value
$8.21 per share

Miscellaneous

Free Float
63,017,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.87

Key Executives

  • Terry J. RosenTerry J. Rosen
    Chairman & Chief Executive Officer
  • Juan Carlos Jaen
    President & Director
  • Jennifer A. JarrettJennifer A. Jarrett
    Chief Operating Officer & Director
  • Robert C. GoeltzRobert C. Goeltz
    Chief Financial Officer
  • Steve Young
    Senior VP-Technology & Quantitative Biology













RCUS Stock - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price forecast for 2023?

9 equities research analysts have issued 12 month price objectives for Arcus Biosciences' stock. Their RCUS share price forecasts range from $33.00 to $51.00. On average, they expect the company's share price to reach $41.44 in the next twelve months. This suggests a possible upside of 101.9% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2023?

Arcus Biosciences' stock was trading at $20.68 on January 1st, 2023. Since then, RCUS stock has decreased by 0.7% and is now trading at $20.53.
View the best growth stocks for 2023 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its earnings results on Tuesday, May, 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.06) by $0.03. The business earned $25 million during the quarter, compared to the consensus estimate of $22.47 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 41.22% and a negative net margin of 233.41%. The business's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period last year, the company posted ($0.96) EPS.

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.87%), State Street Corp (7.52%), FMR LLC (4.53%), Dimensional Fund Advisors LP (1.79%), Pictet Asset Management SA (1.76%) and Bank of America Corp DE (1.57%). Insiders that own company stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $20.53.

How much money does Arcus Biosciences make?

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.50 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.

How many employees does Arcus Biosciences have?

The company employs 366 workers across the globe.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -